328 related articles for article (PubMed ID: 16640847)
41. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine.
Arístegui J; Usonis V; Coovadia H; Riedemann S; Win KM; Gatchalian S; Bock HL
Int J Infect Dis; 2003 Jun; 7(2):143-51. PubMed ID: 12839717
[TBL] [Abstract][Full Text] [Related]
42. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
Shao PL; Lu CY; Hsieh YC; Bock HL; Huang LM;
J Formos Med Assoc; 2011 Jun; 110(6):415-22. PubMed ID: 21741011
[TBL] [Abstract][Full Text] [Related]
43. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
[TBL] [Abstract][Full Text] [Related]
44. The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants.
Prymula R; David MP; Lefevre I; Kohl I; Stefkovicová M
Hum Vaccin; 2007; 3(4):121-6. PubMed ID: 17404515
[TBL] [Abstract][Full Text] [Related]
45. Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugate vaccine, administered in single injection a.
Calbo F; Dal-Ré R; Díez-Delgado J; Oña S; Sánchez-Prados F; García-Corbeira P;
Med Clin (Barc); 2002 Jan; 118(1):1-4. PubMed ID: 11803003
[TBL] [Abstract][Full Text] [Related]
46. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
Dhillon S
BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
[TBL] [Abstract][Full Text] [Related]
47. DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.
Gunardi H; Rusmil K; Fadlyana E; Soedjatmiko ; Dhamayanti M; Sekartini R; Tarigan R; Satari HI; Medise BE; Sari RM; Bachtiar NS; Kartasasmita CB; Hadinegoro SRS
BMC Pediatr; 2018 May; 18(1):177. PubMed ID: 29804542
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
[TBL] [Abstract][Full Text] [Related]
49. Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants.
Gandhi DJ; Dhaded SM; Ravi MD; Dubey AP; Kundu R; Lalwani SK; Chhatwal J; Mathew LG; Gupta M; Sharma SD; Bavdekar SB; Jayanth MV; Ravinuthala S; Sil A; Dhingra MS
Hum Vaccin Immunother; 2016 Apr; 12(4):946-54. PubMed ID: 26580093
[TBL] [Abstract][Full Text] [Related]
50. Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine.
Sharma H; Yadav S; Lalwani S; Kapre S; Jadhav S; Parekh S; Palkar S; Ravetkar S; Bahl S; Kumar R; Shewale S
Vaccine; 2013 Jan; 31(3):444-7. PubMed ID: 23196204
[TBL] [Abstract][Full Text] [Related]
51. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
Avdicova M; Crasta PD; Hardt K; Kovac M
Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers.
Martinón-Torres F; Diez-Domingo J; Feroldi E; Jordanov E; B'Chir S; Da Costa X
Pediatr Infect Dis J; 2019 Mar; 38(3):317-322. PubMed ID: 30408001
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
[TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.
Kanra G; Kara A; Demiralp O; Contorni M; Hilbert AK; Spyr C; Viviani S
Hum Vaccin; 2006; 2(4):155-60. PubMed ID: 17012890
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
[TBL] [Abstract][Full Text] [Related]
56. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age.
Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M
Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777
[TBL] [Abstract][Full Text] [Related]
57. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration.
Madhi SA; López P; Zambrano B; Jordanov E; B'Chir S; Noriega F; Feroldi E
Hum Vaccin Immunother; 2019; 15(3):658-668. PubMed ID: 30513252
[TBL] [Abstract][Full Text] [Related]
58. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P
Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582
[TBL] [Abstract][Full Text] [Related]
60. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.
Boef AGC; van der Klis FRM; Berbers GAM; Buisman AM; Sanders EAM; Kemmeren JM; van der Ende A; de Melker HE; Rots NY; Knol MJ
Vaccine; 2018 Jan; 36(3):400-407. PubMed ID: 29223483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
